Search Results for "Where To Buy Pirfenidone"

18:55 EDT 19th April 2015 | BioPortfolio

Matching Channels

None

Matching News

FDA Approves Esbriet (pirfenidone) for Idiopathic Pulmonary Fibrosis

October 15, 2014 -- The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a condition i...

FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) in the United States. IPF is a fatal di...

Idiopathic pulmonary fibrosis drugs from Roche, Boehringer win FDA approval

The FDA has approved Roche's Esbriet, or pirfenidone, and Boehringer Ingelheim's Ofev, or nintedanib, as treatments for idio -More- 

Roche's Esbriet Gets US FDA Nod for IPF Treatment

The US FDA has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech, as a treatment for idiopathic pulmonary fibrosis (IPF).

FDA Approves Two Drugs for Idiopathic Pulmonary Fibrosis

The US Food and Drug Administration has approved nintedanib (Ofev) and pirfenidone (Esbriet) for the treatment of idiopathic pulmonary fibrosis. FDA Approvals

Genentech's IPF-treating drug Esbriet receives FDA approval

Roche Group subsidiary Genentech has received approval from US Food and Drug Administration (FDA) for Esbriet (pirfenidone) drug to treat patients with idiopathic pulmonary fibrosis (IPF).

FDA approves Esbriet to treat idiopathic pulmonary fibrosis

The U.S. Food and Drug Administration today approved Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF).

Matching PubMed Articles

Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein‑47 and collagen type I in rat hepatic stellate cells in vitro.

Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose‑dependent effects of pirfenidone on t...

Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC-MS/MS.

A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...

Sensitivity Analyses of the Change in Forced Vital Capacity in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Forced vital capacity (FVC) outcomes in clinical trials in idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducte...

Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis.

Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement